Sacubitril is a pharmacological agent primarily used in the treatment of heart failure. It functions as a neprilysin inhibitor, which enhances the levels of natriuretic peptides, leading to vasodilation, reduced blood pressure, and decreased cardiac workload. The substance is often combined with valsartan, an angiotensin receptor blocker, to improve therapeutic outcomes in patients with heart failure with reduced ejection fraction. Sacubitril is characterized by its molecular formula, which reflects its complex structure, and it exhibits a moderate solubility in water, making it suitable for oral administration. The compound is typically administered in the form of a prodrug, which is metabolized in the body to its active form. Its pharmacokinetics involve extensive metabolism, primarily by the liver, and it has a relatively long half-life, allowing for once or twice daily dosing. As with many medications, potential side effects include hypotension, hyperkalemia, and renal impairment, necessitating careful monitoring in clinical settings. Overall, sacubitril represents a significant advancement in heart failure management, offering a novel mechanism of action compared to traditional therapies.

Sacubitril

565453-99-8: Sacubitril is a pharmacological agent primarily used in the treatment of heart failure. It functions as a neprilysin inhibitor, which enhances the levels of natriuretic peptides, leading to vasodilation, reduced blood pressure, and decreased cardiac workload. The substance is often combined with valsartan, an angiotensin receptor blocker, to improve therapeutic outcomes in patients with heart failure with reduced ejection fraction. Sacubitril is characterized by its molecular formula, which reflects its complex structure, and it exhibits a moderate solubility in water, making it suitable for oral administration. The compound is typically administered in the form of a prodrug, which is metabolized in the body to its active form. Its pharmacokinetics involve extensive metabolism, primarily by the liver, and it has a relatively long half-life, allowing for once or twice daily dosing. As with many medications, potential side effects include hypotension, hyperkalemia, and renal impairment, necessitating careful monitoring in clinical settings. Overall, sacubitril represents a significant advancement in heart failure management, offering a novel mechanism of action compared to traditional therapies.

CAS 565453-99-8

Sacubitril

Sacubitril Tromethamine

Ref: ST-EA-CP-S18142